Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06492486 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Glioma Adaptive Radiotherapy With Development of an Artificial Intelligence Workflow

Study acronym: GLADIATOR
StatusRecruiting
PhasePhase 2
Started2026-07-27
View on ClinicalTrials.gov ↗

Amendment history

2026-08-13
notable
Study Status, Contacts/Locations v4
Recruitment opened
Start dateestimated 2025-11-30→confirmed 2026-07-27
Study sites0→1
2025-09-15
minor
Study Status v3
Start date2025-05-31→2025-11-30
2025-04-08
minor
Study Status v2
Start date2025-01-01→2025-05-31
2024-11-18
minor
Study Status v1
Start date2024-08-01→2025-01-01
2024-07-02
minor
Original filing
666 trials monitored
See 45 trials at risk
666 trials monitored
See 38 trials at risk
Gliomas are common primary brain tumors in adults. Gliomas can be classified into different types based on tumor grade, histopathological features, and molecular characteristics. The common types of diffuse gliomas include glioblastoma, astrocytoma, and oligodendroglioma. The standard treatment for diffuse gliomas includes surgery followed by radiation and chemotherapy. As per standard institutional practice, a uniform dose of radiation is delivered to the disease area and MRI is done before and after the treatment. In this study, MRI and PET scan will be done before starting the treatment and standard dose of radiation will be delivered. The interval imaging will be done twice during the course of treatment with MRI and PET, followed by dose modifications. The CT, MRI, and PET will be combined. Based on PET imaging, specific dose will be altered and delivered to specific areas. Dose modification will be done with the help of artificial intelligence. Participant's assessment will be done at regular intervals. Modifications in radiation plans are done based on the changes in disease seen in scans is likely to improve the accuracy of RT treatments. Dose modifications based on imaging to resistant areas will help achieve better tumor control, reduce treatment-related toxicities, precise delivery of the RT and adjusting doses to the organs at risk (OAR) and changes in disease leading to better treatment compliance. Creating an artificial intelligence framework in radiation oncology promises to improve quality of workflow, treatment planning and RT delivery. The aim of the study is to develop an artificial intelligence workflow for treatment of glioma with adaptive radiotherapy. This study will be conducted in Tata Memorial Centre on a population of 60 patients for a duration of 2 years. The total study duration is 4 years.
Trial Details
NCT Number NCT06492486
Lead Sponsor Tata Memorial Centre
Conditions Diffuse Glioma, Glioblastoma, Adaptive Radiotherapy, Artificial Intelligence
Enrollment 60 participants
Start Date 2026-07-27
Primary Completion 2028-07-30 (estimated)
Study Completion 2028-07-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-17